{"gene":"CLN6","run_date":"2026-04-28T17:28:52","timeline":{"discoveries":[{"year":2001,"finding":"CLN6 encodes a novel ~36 kDa transmembrane protein with seven predicted transmembrane domains; loss-of-function mutations (stop codon, codon deletion, frameshift) in this gene cause variant late-infantile neuronal ceroid lipofuscinosis in humans and the nclf mouse.","method":"Positional cloning, DNA sequencing of patient and nclf mouse chromosomes, mutational analysis","journal":"American journal of human genetics","confidence":"High","confidence_rationale":"Tier 1-2 — independently identified by two concurrent papers using positional cloning and mutation identification in multiple species","pmids":["11791207","11727201"],"is_preprint":false},{"year":2004,"finding":"CLN6 protein (~27-30 kDa) resides in the endoplasmic reticulum (ER) and does not traffic to cis-Golgi or lysosomes; disease-causing single-amino-acid mutants are also retained in the ER.","method":"Immunofluorescence microscopy with ER/Golgi/lysosomal markers, GFP-tagged CLN6 expression in HEK293 cells, Western blotting with peptide-specific antibodies","journal":"Experimental cell research / Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — replicated independently by two labs using orthogonal methods (immunofluorescence, tagged constructs, antibody detection)","pmids":["15265688","15010453"],"is_preprint":false},{"year":2004,"finding":"CLN6 forms homodimers, as shown by cross-linking experiments; pathogenic mutations do not prevent dimerization.","method":"Cross-linking experiments and immunoblot analysis in transfected BHK21 cells","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 — single lab, biochemical cross-linking with orthogonal confirmation by expression studies","pmids":["15010453"],"is_preprint":false},{"year":2004,"finding":"Deficiency of CLN6 causes strongly reduced lysosomal degradation of endocytosed arylsulfatase A in patient fibroblasts and animal model cells, while cathepsin D synthesis, sorting, and processing are unaffected, indicating that ER-resident CLN6 is required for normal lysosomal degradative function.","method":"Pulse-chase labeling followed by immunoprecipitation of cathepsin D; lysosomal degradation assay of endocytosed arylsulfatase A in CLN6-deficient fibroblasts from human patients, sheep, and mouse","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — multiple CLN6-deficient cell models (human, sheep, mouse) tested with orthogonal biochemical assays","pmids":["15010453"],"is_preprint":false},{"year":2007,"finding":"CLN6 topology: N-terminal domain is cytoplasmic, C-terminus is luminal, with seven transmembrane domains. ER retention requires both the N-terminal cytosolic domain and transmembrane domains 6 and 7. A dilysine motif partially contributes to ER localization, while a triple arginine cluster and dileucine motif do not affect ER retention.","method":"Differential membrane permeabilization with two distinct antibodies, confocal immunofluorescence microscopy, mutational analysis of retention signals in BHK and neuronal cells","journal":"Molecular membrane biology","confidence":"High","confidence_rationale":"Tier 1-2 — topology determined by differential permeabilization plus mutagenesis of multiple retention signals","pmids":["17453415"],"is_preprint":false},{"year":2007,"finding":"CLN6 homodimerization, demonstrated by expression analyses of fusion and deletion constructs, may contribute to ER retention by interaction with membrane-associated factors.","method":"Expression of fusion and deletion constructs in non-neuronal and neuronal cells, confocal microscopy","journal":"Molecular membrane biology","confidence":"Medium","confidence_rationale":"Tier 2 — single lab, multiple construct analyses with consistent outcome","pmids":["17453415"],"is_preprint":false},{"year":2009,"finding":"CLN6 protein physically interacts with CRMP-2 (collapsin response mediator protein-2); loss of CLN6 reduces CRMP-2 levels in the nclf mouse brain (especially thalamus) and impairs hippocampal neuron maturation in vitro.","method":"Co-immunoprecipitation/interaction assay, Western blot, hippocampal neuron cultures from nclf mice, DRG repulsion assay","journal":"Journal of neuroscience research","confidence":"Medium","confidence_rationale":"Tier 3 — single lab, interaction identified with follow-up functional assays but not fully reconstituted","pmids":["19235893"],"is_preprint":false},{"year":2009,"finding":"Pathogenic CLN6 mutants (G123D and M241T) are rapidly degraded via proteasome-mediated ERAD; they associate with ERAD components Derlin-1 and p97, and knockdown of SEL1L (an E3 ubiquitin ligase complex member) rescues mutant CLN6 protein levels.","method":"Proteasome inhibitor treatment, co-immunoprecipitation with Derlin-1 and p97, siRNA knockdown of SEL1L in neuronal-derived human cells","journal":"Bioscience reports","confidence":"Medium","confidence_rationale":"Tier 2 — single lab with multiple orthogonal approaches (inhibitors, Co-IP, knockdown)","pmids":["18811591"],"is_preprint":false},{"year":2010,"finding":"Pathogenic mutations in CLN6 (p.Gly123Asp, p.Ile154del, p.Arg106ProfsX26) reduce the rate of synthesis and stability of CLN6 protein in a mutation-dependent manner; the truncated p.Arg106ProfsX26 mutant (identical to nclf mouse mutation) is rapidly degraded via both proteasomal and lysosomal pathways, but none of the mutations prevent CLN6 dimerization.","method":"Pulse-chase metabolic labeling, proteasomal and lysosomal inhibitor treatment, expression studies in patient-derived and transfected cells","journal":"Human mutation","confidence":"Medium","confidence_rationale":"Tier 2 — single lab, multiple mutations and orthogonal inhibitor approaches","pmids":["20020536"],"is_preprint":false},{"year":2012,"finding":"CLN6 deficiency disrupts the autophagy-lysosome degradation pathway; nclf mouse brains show age-dependent increases in LC3-II, ubiquitinated proteins, and p62-positive neuronal aggregates, indicating impaired autophagosome-lysosome fusion. Mutant Cln6 protein undergoes proteasomal degradation without inducing ER stress or unfolded protein response.","method":"Western blot for autophagy markers (LC3-II, p62, ubiquitin), proteasomal inhibitor treatment, ER stress marker analysis, immunofluorescence in nclf mouse brain","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 — single lab, multiple orthogonal markers in mouse model","pmids":["22536393"],"is_preprint":false},{"year":2017,"finding":"CLN6 physically interacts with ER-anchored αB-crystallin and functions as a downstream effector to prevent aberrant protein aggregate formation; CLN6 knockdown abolishes anti-aggregate activity and CLN6 overexpression enhances it. This anti-aggregate activity requires an intact autophagy-lysosome system.","method":"Co-immunoprecipitation of ER-anchored αBC binding partners, CLN6 siRNA knockdown and overexpression in HeLa cells, protein aggregation assay, lysosomal inhibitor treatment","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 — single lab, reciprocal gain/loss-of-function with orthogonal approaches","pmids":["28476624"],"is_preprint":false},{"year":2020,"finding":"CLN6 forms an obligate complex with CLN8 (termed EGRESS: ER-to-Golgi relaying of enzymes of the lysosomal system) to recruit lysosomal enzymes at the ER and promote their transfer to the Golgi. The second luminal loop of CLN6 is required for interaction with lysosomal enzymes but is dispensable for interaction with CLN8. CLN6 deficiency causes inefficient ER export of lysosomal enzymes and reduced lysosomal enzyme levels. Mice lacking both CLN6 and CLN8 show no aggravated pathology compared with single knockouts, confirming the two proteins act as a functional unit.","method":"Co-immunoprecipitation, protein trafficking assays, CLN6 loop mutagenesis, in vitro and in vivo lysosomal enzyme quantification, double-knockout mouse analysis","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal methods (Co-IP, mutagenesis, in vivo double KO epistasis, trafficking assays) in single rigorous study","pmids":["32597833"],"is_preprint":false},{"year":2020,"finding":"Graded reduction in CLN6's anti-aggregate activity correlates with disease severity: the late infantile-onset nclf truncation mutant (Arg106ProfsX) abolishes anti-aggregate activity, while adult-onset missense mutants (Arg149Cys, Arg149His) retain partial activity against aggregation-prone αBC mutants.","method":"Protein aggregation assays with CLN6 disease mutants overexpressed in HeLa cells, testing activity against multiple αBC aggregation-prone variants","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 — single lab with multiple mutants and substrates, mechanistically informative","pmids":["32171521"],"is_preprint":false},{"year":2021,"finding":"CLN6 deficiency selectively reduces the lysosomal levels of multiple N-glycosylated soluble hydrolases, including several other NCL proteins, as determined by comparative proteomics of isolated lysosomal fractions; confirmed by Western blot and enzymatic activity assays.","method":"Proteomic analysis of isolated lysosomal fractions from nclf mouse liver, Western blotting, enzymatic activity assays","journal":"Proteomics","confidence":"Medium","confidence_rationale":"Tier 2 — single lab, orthogonal validation (proteomics + Western + enzyme assay) in mouse model","pmids":["34432360"],"is_preprint":false},{"year":2021,"finding":"CLN6's luminal tail (C-terminal domain) is required for maintaining anti-aggregate activity when co-expressed with truncated CLN6 mutants; the S132CfsX18 truncated mutant nullifies the anti-aggregate activity of co-expressed P299L CLN6 missense mutant through a dominant-negative mechanism involving the luminal tail.","method":"Co-expression of CLN6 mutant combinations in cells, protein aggregation assays, deletion and alanine substitution mutagenesis of CLN6 C-terminus","journal":"Biomedical research (Tokyo, Japan)","confidence":"Medium","confidence_rationale":"Tier 2 — single lab, systematic mutagenesis with functional readout","pmids":["34380921"],"is_preprint":false},{"year":2024,"finding":"Pro-cathepsin D (proCTSD) prevents aberrant protein aggregation through functional association with CLN6 at the ER membrane; CLN6 depletion abolishes proCTSD's anti-aggregate activity. CTSD was identified as a binding partner of ER-anchored αBC and its pro-peptide integrity is required for anti-aggregate function.","method":"Co-immunoprecipitation of ER-anchored αBC binding partners (identifying proCTSD), CLN6 knockdown, CTSD variant overexpression, protein aggregation assays in HeLa cells","journal":"Molecular genetics and metabolism","confidence":"Medium","confidence_rationale":"Tier 2 — single lab, multiple orthogonal approaches (Co-IP, knockdown, mutant analysis)","pmids":["39032464"],"is_preprint":false}],"current_model":"CLN6 is a non-glycosylated polytopic ER-resident membrane protein (7 transmembrane domains, cytoplasmic N-terminus, luminal C-terminus) that forms an obligate complex with CLN8 (the EGRESS complex) to recruit lysosomal enzymes at the ER and facilitate their transfer to the Golgi, thereby supporting lysosome biogenesis; CLN6 also homodimerizes, interacts with CRMP-2 and pro-cathepsin D, and suppresses aberrant protein aggregation at the ER through the autophagy-lysosome system, while pathogenic mutations lead to rapid proteasome/ERAD-mediated degradation of the mutant protein and downstream lysosomal dysfunction."},"narrative":{"teleology":[{"year":2001,"claim":"Positional cloning identified CLN6 as the gene mutated in variant late-infantile neuronal ceroid lipofuscinosis (vLINCL) in both humans and the nclf mouse, establishing that this novel seven-transmembrane-domain protein is essential for neuronal survival.","evidence":"Positional cloning and mutation analysis in patient families and the nclf mouse model","pmids":["11791207","11727201"],"confidence":"High","gaps":["Subcellular localization of CLN6 was unknown","Molecular function and pathway involvement were uncharacterized","No protein-level studies had been performed"]},{"year":2004,"claim":"CLN6 was shown to be an ER-resident protein that homodimerizes and whose deficiency impairs lysosomal degradative capacity without affecting cathepsin D processing, establishing that an ER protein can remotely control lysosomal function.","evidence":"Immunofluorescence with organelle markers, GFP-tagged CLN6, cross-linking, and lysosomal degradation assays in patient/animal fibroblasts","pmids":["15265688","15010453"],"confidence":"High","gaps":["The mechanism by which an ER protein influences lysosomal enzyme content was unknown","Identity of direct binding partners mediating lysosomal enzyme trafficking was not established","Topology and ER retention determinants were not yet mapped"]},{"year":2007,"claim":"Mapping of CLN6 topology (cytoplasmic N-terminus, luminal C-terminus, 7 TMs) and identification of ER-retention determinants in the N-terminal cytosolic domain and TMs 6–7 defined the structural framework for understanding CLN6 function.","evidence":"Differential permeabilization, confocal microscopy, and systematic mutagenesis of retention signals in BHK and neuronal cells","pmids":["17453415"],"confidence":"High","gaps":["No direct cargo-binding activity had been demonstrated","Functional significance of homodimerization remained unclear"]},{"year":2009,"claim":"Two distinct aspects of CLN6 biology were revealed: interaction with the neurodevelopmental protein CRMP-2, linking CLN6 to neuronal maturation, and demonstration that pathogenic CLN6 mutants are degraded via ERAD involving Derlin-1, p97, and the SEL1L-dependent ubiquitin ligase.","evidence":"Co-immunoprecipitation of CLN6–CRMP-2; proteasome inhibitors, Co-IP with ERAD components, and SEL1L siRNA rescue in neuronal-derived cells","pmids":["19235893","18811591"],"confidence":"Medium","gaps":["CLN6–CRMP-2 interaction lacks reconstitution with purified proteins","Whether ERAD-mediated loss of mutant CLN6 is the primary pathogenic mechanism versus loss of function was unclear","Relationship between CRMP-2 interaction and lysosomal enzyme trafficking was not addressed"]},{"year":2010,"claim":"Pulse-chase analysis of multiple pathogenic CLN6 mutations showed mutation-dependent effects on protein synthesis rate and stability, with some mutants degraded by both proteasomal and lysosomal pathways, yet none lost the capacity to dimerize.","evidence":"Pulse-chase metabolic labeling, proteasomal and lysosomal inhibitor treatment in patient-derived and transfected cells","pmids":["20020536"],"confidence":"Medium","gaps":["Functional consequence of retained dimerization by mutants was not tested","Whether residual mutant CLN6 retains partial function was unknown"]},{"year":2012,"claim":"CLN6 deficiency was linked to progressive autophagy–lysosome pathway dysfunction, with accumulation of LC3-II, ubiquitinated proteins, and p62 aggregates in nclf neurons, without triggering the unfolded protein response, clarifying that pathology stems from downstream lysosomal failure rather than ER stress.","evidence":"Western blot for autophagy markers, ER stress markers, and proteasomal inhibitor treatment in nclf mouse brain","pmids":["22536393"],"confidence":"Medium","gaps":["Causal direction—whether autophagy block is primary or secondary to lysosomal enzyme depletion—was not resolved","No direct mechanistic link between ER-resident CLN6 and autophagosome–lysosome fusion was identified"]},{"year":2017,"claim":"Discovery that CLN6 physically associates with ER-anchored αB-crystallin and acts as an effector to suppress protein aggregation via the autophagy–lysosome system established an unexpected proteostasis function for CLN6 at the ER.","evidence":"Co-immunoprecipitation, CLN6 siRNA knockdown and overexpression, protein aggregation assays, and lysosomal inhibitor treatment in HeLa cells","pmids":["28476624"],"confidence":"Medium","gaps":["Mechanism by which CLN6 promotes aggregate clearance was not defined","Whether anti-aggregate function is independent of lysosomal enzyme trafficking was not tested"]},{"year":2020,"claim":"The central mechanism of CLN6 was resolved: CLN6 and CLN8 form the EGRESS complex that recruits lysosomal enzymes at the ER for Golgi-directed transport; the second luminal loop of CLN6 mediates enzyme binding while being dispensable for CLN8 interaction, and double-knockout epistasis confirmed the two proteins operate as a single functional unit.","evidence":"Co-immunoprecipitation, lysosomal enzyme trafficking assays, CLN6 luminal loop mutagenesis, and CLN6/CLN8 double-knockout mouse phenotyping","pmids":["32597833"],"confidence":"High","gaps":["Structural basis of enzyme recognition by the EGRESS complex is unknown","How cargo selectivity for N-glycosylated soluble hydrolases is achieved is not established","Whether EGRESS interacts directly with COPII coat components was not tested"]},{"year":2020,"claim":"Genotype–phenotype correlation was mechanistically grounded: graded loss of CLN6 anti-aggregate activity correlated with disease severity, with the nclf truncation abolishing activity and adult-onset missense mutations retaining partial function.","evidence":"Protein aggregation assays with multiple CLN6 disease mutants tested against αBC aggregation-prone variants in HeLa cells","pmids":["32171521"],"confidence":"Medium","gaps":["Whether residual anti-aggregate activity predicts disease course in patients was not tested clinically","Relationship between EGRESS function and anti-aggregate activity was not disentangled"]},{"year":2021,"claim":"Proteomic analysis confirmed that CLN6 deficiency broadly depletes N-glycosylated soluble hydrolases from lysosomes, including multiple NCL-related enzymes, validating the EGRESS model at the organelle level; separately, the luminal C-terminal tail was shown to be critical for anti-aggregate activity and a truncated CLN6 mutant exerts dominant-negative effects.","evidence":"Proteomic analysis of isolated lysosomal fractions from nclf liver, Western blot, enzyme assays; co-expression mutagenesis and aggregation assays","pmids":["34432360","34380921"],"confidence":"Medium","gaps":["Mechanism of dominant-negative effect through the luminal tail is not resolved at a structural level","Whether tissue-specific differences in lysosomal enzyme depletion exist was not explored"]},{"year":2024,"claim":"Pro-cathepsin D was identified as a functional partner of CLN6 in the anti-aggregate pathway, requiring CLN6 for its ER-localized anti-aggregate activity and linking a known NCL enzyme to CLN6-dependent proteostasis at the ER.","evidence":"Co-immunoprecipitation of ER-anchored αBC partners identifying proCTSD, CLN6 knockdown, CTSD variant overexpression, aggregation assays in HeLa cells","pmids":["39032464"],"confidence":"Medium","gaps":["Whether proCTSD is an EGRESS cargo that also has a pre-export ER function, or whether these are separable roles, is unresolved","Direct physical interaction between CLN6 and proCTSD has not been demonstrated with purified components"]},{"year":null,"claim":"Key open questions include the structural basis of CLN6–CLN8 EGRESS complex assembly and cargo recognition, whether CLN6's anti-aggregate function is mechanistically distinct from its enzyme-trafficking role, how EGRESS interfaces with COPII-mediated ER export, and whether therapeutic stabilization of mutant CLN6 can restore lysosomal biogenesis in vivo.","evidence":"","pmids":[],"confidence":"High","gaps":["No high-resolution structure of CLN6 or the EGRESS complex exists","Mechanistic relationship between EGRESS trafficking function and anti-aggregate function is unresolved","COPII interaction and ER-exit mechanism for the EGRESS–cargo complex are uncharacterized"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[11,13]},{"term_id":"GO:0038024","term_label":"cargo receptor activity","supporting_discovery_ids":[11]}],"localization":[{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[1,4,11]}],"pathway":[{"term_id":"R-HSA-9612973","term_label":"Autophagy","supporting_discovery_ids":[9,10]},{"term_id":"R-HSA-9609507","term_label":"Protein localization","supporting_discovery_ids":[11,13]},{"term_id":"R-HSA-1852241","term_label":"Organelle biogenesis and maintenance","supporting_discovery_ids":[3,11,13]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[7,8]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[0,12]}],"complexes":["EGRESS complex (CLN6–CLN8)"],"partners":["CLN8","CRMP2","CRYAB","CTSD","DERL1","VCP","SEL1L"],"other_free_text":[]},"mechanistic_narrative":"CLN6 is an ER-resident polytopic membrane protein that functions centrally in lysosome biogenesis by forming an obligate complex with CLN8 (the EGRESS complex) to recruit soluble lysosomal enzymes at the ER and facilitate their COPII-mediated transport to the Golgi [PMID:32597833]. CLN6 possesses seven transmembrane domains with a cytoplasmic N-terminus and luminal C-terminus, homodimerizes, and is retained in the ER through determinants in its N-terminal cytosolic domain and transmembrane domains 6–7 [PMID:15010453, PMID:17453415]. Beyond enzyme trafficking, CLN6 cooperates with ER-anchored αB-crystallin and pro-cathepsin D to suppress aberrant protein aggregation through the autophagy–lysosome system, and loss of CLN6 causes accumulation of autophagic substrates and ubiquitinated aggregates in neurons [PMID:28476624, PMID:22536393, PMID:39032464]. Loss-of-function mutations in CLN6 cause variant late-infantile neuronal ceroid lipofuscinosis, with pathogenic mutants undergoing rapid proteasome/ERAD-mediated degradation and graded loss of anti-aggregate activity correlating with disease severity [PMID:11791207, PMID:18811591, PMID:32171521]."},"prefetch_data":{"uniprot":{"accession":"Q9NWW5","full_name":"Ceroid-lipofuscinosis neuronal protein 6","aliases":[],"length_aa":311,"mass_kda":35.9,"function":"","subcellular_location":"Endoplasmic reticulum membrane; Endoplasmic reticulum","url":"https://www.uniprot.org/uniprotkb/Q9NWW5/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CLN6","classification":"Not Classified","n_dependent_lines":4,"n_total_lines":1208,"dependency_fraction":0.0033112582781456954},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/CLN6","total_profiled":1310},"omim":[{"mim_id":"611274","title":"GLAUCOMA 1, OPEN ANGLE, N; GLC1N","url":"https://www.omim.org/entry/611274"},{"mim_id":"610951","title":"CEROID LIPOFUSCINOSIS, NEURONAL, 7; CLN7","url":"https://www.omim.org/entry/610951"},{"mim_id":"607837","title":"CLN8 TRANSMEMBRANE ER AND ERGIC PROTEIN; CLN8","url":"https://www.omim.org/entry/607837"},{"mim_id":"606725","title":"CLN6 TRANSMEMBRANE ER PROTEIN; CLN6","url":"https://www.omim.org/entry/606725"},{"mim_id":"601780","title":"CEROID LIPOFUSCINOSIS, NEURONAL, 6A; CLN6A","url":"https://www.omim.org/entry/601780"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Endoplasmic reticulum","reliability":"Approved"},{"location":"Nucleoli","reliability":"Additional"},{"location":"Vesicles","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/CLN6"},"hgnc":{"alias_symbol":["FLJ20561","HsT18960","nclf"],"prev_symbol":[]},"alphafold":{"accession":"Q9NWW5","domains":[{"cath_id":"1.20.190","chopping":"41-306","consensus_level":"medium","plddt":92.6908,"start":41,"end":306}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9NWW5","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9NWW5-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9NWW5-F1-predicted_aligned_error_v6.png","plddt_mean":84.94},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CLN6","jax_strain_url":"https://www.jax.org/strain/search?query=CLN6"},"sequence":{"accession":"Q9NWW5","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9NWW5.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9NWW5/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9NWW5"}},"corpus_meta":[{"pmid":"11791207","id":"PMC_11791207","title":"Mutations in a novel CLN6-encoded transmembrane protein cause variant neuronal ceroid lipofuscinosis in man and mouse.","date":"2001","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/11791207","citation_count":165,"is_preprint":false},{"pmid":"11727201","id":"PMC_11727201","title":"The gene mutated in variant late-infantile neuronal ceroid lipofuscinosis (CLN6) and in nclf mutant mice encodes a novel predicted transmembrane protein.","date":"2001","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/11727201","citation_count":147,"is_preprint":false},{"pmid":"21549341","id":"PMC_21549341","title":"Kufs disease, the major adult form of neuronal ceroid lipofuscinosis, caused by mutations in CLN6.","date":"2011","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/21549341","citation_count":108,"is_preprint":false},{"pmid":"9600738","id":"PMC_9600738","title":"Neuronal ceroid lipofuscinosis (nclf), a new disorder of the mouse linked to chromosome 9.","date":"1998","source":"American journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/9600738","citation_count":104,"is_preprint":false},{"pmid":"16137566","id":"PMC_16137566","title":"Glial activation spreads from specific cerebral foci and precedes neurodegeneration in presymptomatic ovine neuronal ceroid lipofuscinosis (CLN6).","date":"2005","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/16137566","citation_count":97,"is_preprint":false},{"pmid":"15265688","id":"PMC_15265688","title":"CLN6, which is associated with a lysosomal storage disease, is an endoplasmic reticulum protein.","date":"2004","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/15265688","citation_count":88,"is_preprint":false},{"pmid":"15010453","id":"PMC_15010453","title":"Defective endoplasmic reticulum-resident membrane protein CLN6 affects lysosomal degradation of endocytosed arylsulfatase A.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15010453","citation_count":78,"is_preprint":false},{"pmid":"32597833","id":"PMC_32597833","title":"A CLN6-CLN8 complex recruits lysosomal enzymes at the ER for Golgi transfer.","date":"2020","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/32597833","citation_count":68,"is_preprint":false},{"pmid":"12815591","id":"PMC_12815591","title":"Spectrum of CLN6 mutations in variant late infantile neuronal ceroid lipofuscinosis.","date":"2003","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/12815591","citation_count":64,"is_preprint":false},{"pmid":"17046213","id":"PMC_17046213","title":"A missense mutation (c.184C>T) in ovine CLN6 causes neuronal ceroid lipofuscinosis in Merino sheep whereas affected South Hampshire sheep have reduced levels of CLN6 mRNA.","date":"2006","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/17046213","citation_count":60,"is_preprint":false},{"pmid":"22536393","id":"PMC_22536393","title":"Disruption of the autophagy-lysosome pathway is involved in neuropathology of the nclf mouse model of neuronal ceroid lipofuscinosis.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22536393","citation_count":59,"is_preprint":false},{"pmid":"9733028","id":"PMC_9733028","title":"Ovine neuronal ceroid lipofuscinosis: a large animal model syntenic with the human neuronal ceroid lipofuscinosis variant CLN6.","date":"1998","source":"Journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/9733028","citation_count":59,"is_preprint":false},{"pmid":"21234413","id":"PMC_21234413","title":"A missense mutation in canine CLN6 in an Australian shepherd with neuronal ceroid lipofuscinosis.","date":"2010","source":"Journal of biomedicine & biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/21234413","citation_count":55,"is_preprint":false},{"pmid":"24124525","id":"PMC_24124525","title":"Progressive retinal degeneration and glial activation in the CLN6 (nclf) mouse model of neuronal ceroid lipofuscinosis: a beneficial effect of DHA and curcumin supplementation.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24124525","citation_count":52,"is_preprint":false},{"pmid":"17453415","id":"PMC_17453415","title":"Topology and endoplasmic reticulum retention signals of the lysosomal storage disease-related membrane protein CLN6.","date":"2007","source":"Molecular membrane biology","url":"https://pubmed.ncbi.nlm.nih.gov/17453415","citation_count":41,"is_preprint":false},{"pmid":"31331814","id":"PMC_31331814","title":"Gene Therapy Corrects Brain and Behavioral Pathologies in CLN6-Batten Disease.","date":"2019","source":"Molecular therapy : the journal of the American Society of Gene Therapy","url":"https://pubmed.ncbi.nlm.nih.gov/31331814","citation_count":37,"is_preprint":false},{"pmid":"12673792","id":"PMC_12673792","title":"Novel mutations in the CLN6 gene causing a variant late infantile neuronal ceroid lipofuscinosis.","date":"2003","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/12673792","citation_count":37,"is_preprint":false},{"pmid":"19135028","id":"PMC_19135028","title":"Variant late infantile ceroid lipofuscinoses associated with novel mutations in CLN6.","date":"2009","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/19135028","citation_count":35,"is_preprint":false},{"pmid":"29606505","id":"PMC_29606505","title":"Prevention of Photoreceptor Cell Loss in a Cln6nclf Mouse Model of Batten Disease Requires CLN6 Gene Transfer to Bipolar Cells.","date":"2018","source":"Molecular therapy : the journal of the American Society of Gene Therapy","url":"https://pubmed.ncbi.nlm.nih.gov/29606505","citation_count":34,"is_preprint":false},{"pmid":"19235893","id":"PMC_19235893","title":"Protein product of CLN6 gene responsible for variant late-onset infantile neuronal ceroid lipofuscinosis interacts with CRMP-2.","date":"2009","source":"Journal of neuroscience research","url":"https://pubmed.ncbi.nlm.nih.gov/19235893","citation_count":33,"is_preprint":false},{"pmid":"30561534","id":"PMC_30561534","title":"Kufs disease due to mutation of CLN6: clinical, pathological and molecular genetic features.","date":"2019","source":"Brain : a journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/30561534","citation_count":30,"is_preprint":false},{"pmid":"12946273","id":"PMC_12946273","title":"Enhanced expression of manganese-dependent superoxide dismutase in human and sheep CLN6 tissues.","date":"2003","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/12946273","citation_count":30,"is_preprint":false},{"pmid":"28065762","id":"PMC_28065762","title":"Characterisation of early changes in ovine CLN5 and CLN6 Batten disease neural cultures for the rapid screening of therapeutics.","date":"2017","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/28065762","citation_count":26,"is_preprint":false},{"pmid":"24084090","id":"PMC_24084090","title":"Apoptotic photoreceptor loss and altered expression of lysosomal proteins in the nclf mouse model of neuronal ceroid lipofuscinosis.","date":"2013","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/24084090","citation_count":25,"is_preprint":false},{"pmid":"23789114","id":"PMC_23789114","title":"Altered biometal homeostasis is associated with CLN6 mRNA loss in mouse neuronal ceroid lipofuscinosis.","date":"2013","source":"Biology open","url":"https://pubmed.ncbi.nlm.nih.gov/23789114","citation_count":25,"is_preprint":false},{"pmid":"23516525","id":"PMC_23516525","title":"Increased zinc and manganese in parallel with neurodegeneration, synaptic protein changes and activation of Akt/GSK3 signaling in ovine CLN6 neuronal ceroid lipofuscinosis.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23516525","citation_count":24,"is_preprint":false},{"pmid":"20020536","id":"PMC_20020536","title":"Pathogenic mutations cause rapid degradation of lysosomal storage disease-related membrane protein CLN6.","date":"2010","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/20020536","citation_count":23,"is_preprint":false},{"pmid":"15996215","id":"PMC_15996215","title":"Two novel CLN6 mutations in variant late-infantile neuronal ceroid lipofuscinosis patients of Turkish origin.","date":"2005","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/15996215","citation_count":23,"is_preprint":false},{"pmid":"31807779","id":"PMC_31807779","title":"Neonatal brain-directed gene therapy rescues a mouse model of neurodegenerative CLN6 Batten disease.","date":"2019","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/31807779","citation_count":20,"is_preprint":false},{"pmid":"18811591","id":"PMC_18811591","title":"Cln6 mutants associated with neuronal ceroid lipofuscinosis are degraded in a proteasome-dependent manner.","date":"2009","source":"Bioscience reports","url":"https://pubmed.ncbi.nlm.nih.gov/18811591","citation_count":19,"is_preprint":false},{"pmid":"25992714","id":"PMC_25992714","title":"Sustained Neural Stem Cell-Based Intraocular Delivery of CNTF Attenuates Photoreceptor Loss in the nclf Mouse Model of Neuronal Ceroid Lipofuscinosis.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25992714","citation_count":18,"is_preprint":false},{"pmid":"26161747","id":"PMC_26161747","title":"Rapid and Progressive Regional Brain Atrophy in CLN6 Batten Disease Affected Sheep Measured with Longitudinal Magnetic Resonance Imaging.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26161747","citation_count":18,"is_preprint":false},{"pmid":"10191123","id":"PMC_10191123","title":"Genetic and physical mapping of the CLN6 gene on chromosome 15q21-23.","date":"1999","source":"Molecular genetics and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/10191123","citation_count":18,"is_preprint":false},{"pmid":"22883287","id":"PMC_22883287","title":"Mutation of the CLN6 gene in teenage-onset progressive myoclonus epilepsy.","date":"2012","source":"Pediatric neurology","url":"https://pubmed.ncbi.nlm.nih.gov/22883287","citation_count":17,"is_preprint":false},{"pmid":"17510975","id":"PMC_17510975","title":"Metabolomic investigation of CLN6 neuronal ceroid lipofuscinosis in affected South Hampshire sheep.","date":"2007","source":"Journal of neuroscience research","url":"https://pubmed.ncbi.nlm.nih.gov/17510975","citation_count":17,"is_preprint":false},{"pmid":"33665223","id":"PMC_33665223","title":"Intracranial delivery of AAV9 gene therapy partially prevents retinal degeneration and visual deficits in CLN6-Batten disease mice.","date":"2021","source":"Molecular therapy. Methods & clinical development","url":"https://pubmed.ncbi.nlm.nih.gov/33665223","citation_count":15,"is_preprint":false},{"pmid":"19520283","id":"PMC_19520283","title":"Variant late infantile neuronal ceroid lipofuscinosis (CLN6 gene) in Saudi Arabia.","date":"2009","source":"Pediatric neurology","url":"https://pubmed.ncbi.nlm.nih.gov/19520283","citation_count":15,"is_preprint":false},{"pmid":"32518081","id":"PMC_32518081","title":"Neuronal Ceroid Lipofuscinosis in a Domestic Cat Associated with a DNA Sequence Variant That Creates a Premature Stop Codon in CLN6.","date":"2020","source":"G3 (Bethesda, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/32518081","citation_count":12,"is_preprint":false},{"pmid":"22012656","id":"PMC_22012656","title":"High expression of disease-related Cln6 in the cerebral cortex, purkinje cells, dentate gyrus, and hippocampal ca1 neurons.","date":"2011","source":"Journal of neuroscience research","url":"https://pubmed.ncbi.nlm.nih.gov/22012656","citation_count":11,"is_preprint":false},{"pmid":"30528883","id":"PMC_30528883","title":"Novel mutations in CLN6 cause late-infantile neuronal ceroid lipofuscinosis without visual impairment in two unrelated patients.","date":"2018","source":"Molecular genetics and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/30528883","citation_count":11,"is_preprint":false},{"pmid":"23735787","id":"PMC_23735787","title":"CLN6 disease caused by the same mutation originating in Pakistan has varying pathology.","date":"2013","source":"European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society","url":"https://pubmed.ncbi.nlm.nih.gov/23735787","citation_count":11,"is_preprint":false},{"pmid":"27165443","id":"PMC_27165443","title":"First Japanese variant of late infantile neuronal ceroid lipofuscinosis caused by novel CLN6 mutations.","date":"2016","source":"Brain & development","url":"https://pubmed.ncbi.nlm.nih.gov/27165443","citation_count":11,"is_preprint":false},{"pmid":"21111820","id":"PMC_21111820","title":"The specific loss of GnRH-positive neurons from the hypothalamus of sheep with CLN6 neuronal ceroid lipofuscinosis occurs without glial activation and has only minor effects on reproduction.","date":"2010","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/21111820","citation_count":11,"is_preprint":false},{"pmid":"35012600","id":"PMC_35012600","title":"Neuronal Ceroid Lipofuscinosis Type 6 (CLN6) clinical findings and molecular diagnosis: Costa Rica's experience.","date":"2022","source":"Orphanet journal of rare diseases","url":"https://pubmed.ncbi.nlm.nih.gov/35012600","citation_count":10,"is_preprint":false},{"pmid":"34868216","id":"PMC_34868216","title":"A Novel CLN6 Variant Associated With Juvenile Neuronal Ceroid Lipofuscinosis in Patients With Absence of Visual Loss as a Presenting Feature.","date":"2021","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/34868216","citation_count":10,"is_preprint":false},{"pmid":"30285654","id":"PMC_30285654","title":"A first CLN6 variant case of late infantile neuronal ceroid lipofuscinosis caused by a homozygous mutation in a boy from China: a case report.","date":"2018","source":"BMC medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/30285654","citation_count":10,"is_preprint":false},{"pmid":"34432360","id":"PMC_34432360","title":"CLN6 deficiency causes selective changes in the lysosomal protein composition.","date":"2021","source":"Proteomics","url":"https://pubmed.ncbi.nlm.nih.gov/34432360","citation_count":9,"is_preprint":false},{"pmid":"28476624","id":"PMC_28476624","title":"Identification of CLN6 as a molecular entity of endoplasmic reticulum-driven anti-aggregate activity.","date":"2017","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/28476624","citation_count":8,"is_preprint":false},{"pmid":"10191124","id":"PMC_10191124","title":"Progress toward the cloning of CLN6, the gene underlying a variant LINCL.","date":"1999","source":"Molecular genetics and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/10191124","citation_count":8,"is_preprint":false},{"pmid":"33368303","id":"PMC_33368303","title":"An altered secretome is an early marker of the pathogenesis of CLN6 Batten disease.","date":"2021","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/33368303","citation_count":7,"is_preprint":false},{"pmid":"37246363","id":"PMC_37246363","title":"Characterization of neuropathology in ovine CLN5 and CLN6 neuronal ceroid lipofuscinoses (Batten disease).","date":"2023","source":"Developmental neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/37246363","citation_count":7,"is_preprint":false},{"pmid":"34141843","id":"PMC_34141843","title":"Electroretinography data from ovine models of CLN5 and CLN6 neuronal ceroid lipofuscinoses.","date":"2021","source":"Data in brief","url":"https://pubmed.ncbi.nlm.nih.gov/34141843","citation_count":7,"is_preprint":false},{"pmid":"36632184","id":"PMC_36632184","title":"Progressive MRI brain volume changes in ovine models of CLN5 and CLN6 neuronal ceroid lipofuscinosis.","date":"2023","source":"Brain communications","url":"https://pubmed.ncbi.nlm.nih.gov/36632184","citation_count":7,"is_preprint":false},{"pmid":"31029456","id":"PMC_31029456","title":"Rapid progression of a walking disability in a 5-year-old boy with a CLN6 mutation.","date":"2019","source":"Brain & development","url":"https://pubmed.ncbi.nlm.nih.gov/31029456","citation_count":7,"is_preprint":false},{"pmid":"32171521","id":"PMC_32171521","title":"Implications of graded reductions in CLN6's anti-aggregate activity for the development of the neuronal ceroid lipofuscinoses.","date":"2020","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/32171521","citation_count":6,"is_preprint":false},{"pmid":"37899458","id":"PMC_37899458","title":"Neuronal progenitor cells-based metabolomics study reveals dysregulated lipid metabolism and identifies putative biomarkers for CLN6 disease.","date":"2023","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/37899458","citation_count":5,"is_preprint":false},{"pmid":"10191131","id":"PMC_10191131","title":"Progress toward positional cloning of ovine neuronal ceroid lipofuscinosis, a model of the human late-infantile variant CLN6.","date":"1999","source":"Molecular genetics and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/10191131","citation_count":5,"is_preprint":false},{"pmid":"34380921","id":"PMC_34380921","title":"CLN6's luminal tail-mediated functional interference between CLN6 mutants as a novel pathomechanism for the neuronal ceroid lipofuscinoses.","date":"2021","source":"Biomedical research (Tokyo, Japan)","url":"https://pubmed.ncbi.nlm.nih.gov/34380921","citation_count":4,"is_preprint":false},{"pmid":"23180398","id":"PMC_23180398","title":"CLN6 p.I154del mutation causing late infantile neuronal ceroid lipofuscinosis in a large consanguineous Moroccan family.","date":"2012","source":"Indian journal of pediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/23180398","citation_count":4,"is_preprint":false},{"pmid":"11589004","id":"PMC_11589004","title":"Fine mapping of ovine ceroid lipofuscinosis confirms orthology with CLN6.","date":"2001","source":"European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society","url":"https://pubmed.ncbi.nlm.nih.gov/11589004","citation_count":4,"is_preprint":false},{"pmid":"33024953","id":"PMC_33024953","title":"Moyamoya and progressive myoclonic epilepsy secondary to CLN6 bi-allelic mutations - A previously unreported association.","date":"2020","source":"Epilepsy & behavior reports","url":"https://pubmed.ncbi.nlm.nih.gov/33024953","citation_count":3,"is_preprint":false},{"pmid":"38352418","id":"PMC_38352418","title":"Cellular Modeling of CLN6 with IPSC-derived Neurons and Glia.","date":"2024","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/38352418","citation_count":2,"is_preprint":false},{"pmid":"34597687","id":"PMC_34597687","title":"p.Asn77Lys homozygous CLN6 mutation in two unrelated Japanese patients with Kufs disease, an adult onset neuronal ceroid lipofuscinosis.","date":"2021","source":"Clinica chimica acta; international journal of clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/34597687","citation_count":2,"is_preprint":false},{"pmid":"11589002","id":"PMC_11589002","title":"Analysis of candidate genes in the CLN6 critical region using in silico cloning.","date":"2001","source":"European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society","url":"https://pubmed.ncbi.nlm.nih.gov/11589002","citation_count":2,"is_preprint":false},{"pmid":"40358187","id":"PMC_40358187","title":"Expanded Phenotype of the Cln6 Mouse Model.","date":"2025","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/40358187","citation_count":1,"is_preprint":false},{"pmid":"38382230","id":"PMC_38382230","title":"Whole exome sequencing identifies variable expressivity of CLN6 variants in Progressive myoclonic epilepsy affected families.","date":"2023","source":"Epilepsy research","url":"https://pubmed.ncbi.nlm.nih.gov/38382230","citation_count":1,"is_preprint":false},{"pmid":"38771523","id":"PMC_38771523","title":"A novel homozygous CLN6 Tyr142Cys variant in a nonconsanguineous family with Kufs disease.","date":"2024","source":"Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology","url":"https://pubmed.ncbi.nlm.nih.gov/38771523","citation_count":1,"is_preprint":false},{"pmid":"37383919","id":"PMC_37383919","title":"Rare adult neuronal ceroid lipofuscinosis associated with CLN6 gene mutations: A case report.","date":"2023","source":"World journal of clinical cases","url":"https://pubmed.ncbi.nlm.nih.gov/37383919","citation_count":1,"is_preprint":false},{"pmid":"38927597","id":"PMC_38927597","title":"Neuronal Ceroid Lipofuscinosis in a Mixed-Breed Dog with a Splice Site Variant in CLN6.","date":"2024","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/38927597","citation_count":1,"is_preprint":false},{"pmid":"38866396","id":"PMC_38866396","title":"Neuronal ceroid lipofuscinosis in a Schapendoes dog is caused by a missense variant in CLN6.","date":"2024","source":"Animal genetics","url":"https://pubmed.ncbi.nlm.nih.gov/38866396","citation_count":1,"is_preprint":false},{"pmid":"32269836","id":"PMC_32269836","title":"Modulation of CRMP2 via (S)-Lacosamide shows therapeutic promise but is ultimately ineffective in a mouse model of CLN6-Batten disease.","date":"2019","source":"Neuronal signaling","url":"https://pubmed.ncbi.nlm.nih.gov/32269836","citation_count":1,"is_preprint":false},{"pmid":"39718800","id":"PMC_39718800","title":"CLN6-related continuum phenotype caused by aberrant splicing.","date":"2024","source":"Epilepsia open","url":"https://pubmed.ncbi.nlm.nih.gov/39718800","citation_count":1,"is_preprint":false},{"pmid":"39032464","id":"PMC_39032464","title":"Pro-cathepsin D prevents aberrant protein aggregation dependent on endoplasmic reticulum protein CLN6.","date":"2024","source":"Molecular genetics and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/39032464","citation_count":0,"is_preprint":false},{"pmid":"41827875","id":"PMC_41827875","title":"A Flupirtine Benzyl Carbamate Improves Neurocognitive Deficits and Molecular Pathology in the Cln6 Mouse.","date":"2026","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/41827875","citation_count":0,"is_preprint":false},{"pmid":"35609511","id":"PMC_35609511","title":"Juvenile-Onset Kufs Disease in a Chinese Consanguineous Family due to CLN6 Mutation.","date":"2022","source":"Neuro-degenerative diseases","url":"https://pubmed.ncbi.nlm.nih.gov/35609511","citation_count":0,"is_preprint":false},{"pmid":"35404973","id":"PMC_35404973","title":"Aggregation chimeras provide evidence of in vivo intercellular correction in ovine CLN6 neuronal ceroid lipofuscinosis (Batten disease).","date":"2022","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/35404973","citation_count":0,"is_preprint":false},{"pmid":"40823674","id":"PMC_40823674","title":"Diagnostic analysis of adult neuronal ceroid lipofuscinosis caused by CLN6 gene mutation: a case report.","date":"2025","source":"Clinical parkinsonism & related disorders","url":"https://pubmed.ncbi.nlm.nih.gov/40823674","citation_count":0,"is_preprint":false},{"pmid":"31901039","id":"PMC_31901039","title":"[Genetic study of a family of neuronal ceroid lipofuscinosis caused by a heterozygous mutation of CLN6 gene].","date":"2019","source":"Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/31901039","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":37305,"output_tokens":3736,"usd":0.083977},"stage2":{"model":"claude-opus-4-6","input_tokens":7178,"output_tokens":3296,"usd":0.177435},"total_usd":0.261412,"stage1_batch_id":"msgbatch_011kfMfE81o6CTcyhVUqumuW","stage2_batch_id":"msgbatch_01DTputS6WNkH745x1nVSoBo","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2001,\n      \"finding\": \"CLN6 encodes a novel ~36 kDa transmembrane protein with seven predicted transmembrane domains; loss-of-function mutations (stop codon, codon deletion, frameshift) in this gene cause variant late-infantile neuronal ceroid lipofuscinosis in humans and the nclf mouse.\",\n      \"method\": \"Positional cloning, DNA sequencing of patient and nclf mouse chromosomes, mutational analysis\",\n      \"journal\": \"American journal of human genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — independently identified by two concurrent papers using positional cloning and mutation identification in multiple species\",\n      \"pmids\": [\"11791207\", \"11727201\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"CLN6 protein (~27-30 kDa) resides in the endoplasmic reticulum (ER) and does not traffic to cis-Golgi or lysosomes; disease-causing single-amino-acid mutants are also retained in the ER.\",\n      \"method\": \"Immunofluorescence microscopy with ER/Golgi/lysosomal markers, GFP-tagged CLN6 expression in HEK293 cells, Western blotting with peptide-specific antibodies\",\n      \"journal\": \"Experimental cell research / Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — replicated independently by two labs using orthogonal methods (immunofluorescence, tagged constructs, antibody detection)\",\n      \"pmids\": [\"15265688\", \"15010453\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"CLN6 forms homodimers, as shown by cross-linking experiments; pathogenic mutations do not prevent dimerization.\",\n      \"method\": \"Cross-linking experiments and immunoblot analysis in transfected BHK21 cells\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — single lab, biochemical cross-linking with orthogonal confirmation by expression studies\",\n      \"pmids\": [\"15010453\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Deficiency of CLN6 causes strongly reduced lysosomal degradation of endocytosed arylsulfatase A in patient fibroblasts and animal model cells, while cathepsin D synthesis, sorting, and processing are unaffected, indicating that ER-resident CLN6 is required for normal lysosomal degradative function.\",\n      \"method\": \"Pulse-chase labeling followed by immunoprecipitation of cathepsin D; lysosomal degradation assay of endocytosed arylsulfatase A in CLN6-deficient fibroblasts from human patients, sheep, and mouse\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple CLN6-deficient cell models (human, sheep, mouse) tested with orthogonal biochemical assays\",\n      \"pmids\": [\"15010453\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"CLN6 topology: N-terminal domain is cytoplasmic, C-terminus is luminal, with seven transmembrane domains. ER retention requires both the N-terminal cytosolic domain and transmembrane domains 6 and 7. A dilysine motif partially contributes to ER localization, while a triple arginine cluster and dileucine motif do not affect ER retention.\",\n      \"method\": \"Differential membrane permeabilization with two distinct antibodies, confocal immunofluorescence microscopy, mutational analysis of retention signals in BHK and neuronal cells\",\n      \"journal\": \"Molecular membrane biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — topology determined by differential permeabilization plus mutagenesis of multiple retention signals\",\n      \"pmids\": [\"17453415\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"CLN6 homodimerization, demonstrated by expression analyses of fusion and deletion constructs, may contribute to ER retention by interaction with membrane-associated factors.\",\n      \"method\": \"Expression of fusion and deletion constructs in non-neuronal and neuronal cells, confocal microscopy\",\n      \"journal\": \"Molecular membrane biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — single lab, multiple construct analyses with consistent outcome\",\n      \"pmids\": [\"17453415\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"CLN6 protein physically interacts with CRMP-2 (collapsin response mediator protein-2); loss of CLN6 reduces CRMP-2 levels in the nclf mouse brain (especially thalamus) and impairs hippocampal neuron maturation in vitro.\",\n      \"method\": \"Co-immunoprecipitation/interaction assay, Western blot, hippocampal neuron cultures from nclf mice, DRG repulsion assay\",\n      \"journal\": \"Journal of neuroscience research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — single lab, interaction identified with follow-up functional assays but not fully reconstituted\",\n      \"pmids\": [\"19235893\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Pathogenic CLN6 mutants (G123D and M241T) are rapidly degraded via proteasome-mediated ERAD; they associate with ERAD components Derlin-1 and p97, and knockdown of SEL1L (an E3 ubiquitin ligase complex member) rescues mutant CLN6 protein levels.\",\n      \"method\": \"Proteasome inhibitor treatment, co-immunoprecipitation with Derlin-1 and p97, siRNA knockdown of SEL1L in neuronal-derived human cells\",\n      \"journal\": \"Bioscience reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — single lab with multiple orthogonal approaches (inhibitors, Co-IP, knockdown)\",\n      \"pmids\": [\"18811591\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Pathogenic mutations in CLN6 (p.Gly123Asp, p.Ile154del, p.Arg106ProfsX26) reduce the rate of synthesis and stability of CLN6 protein in a mutation-dependent manner; the truncated p.Arg106ProfsX26 mutant (identical to nclf mouse mutation) is rapidly degraded via both proteasomal and lysosomal pathways, but none of the mutations prevent CLN6 dimerization.\",\n      \"method\": \"Pulse-chase metabolic labeling, proteasomal and lysosomal inhibitor treatment, expression studies in patient-derived and transfected cells\",\n      \"journal\": \"Human mutation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — single lab, multiple mutations and orthogonal inhibitor approaches\",\n      \"pmids\": [\"20020536\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"CLN6 deficiency disrupts the autophagy-lysosome degradation pathway; nclf mouse brains show age-dependent increases in LC3-II, ubiquitinated proteins, and p62-positive neuronal aggregates, indicating impaired autophagosome-lysosome fusion. Mutant Cln6 protein undergoes proteasomal degradation without inducing ER stress or unfolded protein response.\",\n      \"method\": \"Western blot for autophagy markers (LC3-II, p62, ubiquitin), proteasomal inhibitor treatment, ER stress marker analysis, immunofluorescence in nclf mouse brain\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — single lab, multiple orthogonal markers in mouse model\",\n      \"pmids\": [\"22536393\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"CLN6 physically interacts with ER-anchored αB-crystallin and functions as a downstream effector to prevent aberrant protein aggregate formation; CLN6 knockdown abolishes anti-aggregate activity and CLN6 overexpression enhances it. This anti-aggregate activity requires an intact autophagy-lysosome system.\",\n      \"method\": \"Co-immunoprecipitation of ER-anchored αBC binding partners, CLN6 siRNA knockdown and overexpression in HeLa cells, protein aggregation assay, lysosomal inhibitor treatment\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — single lab, reciprocal gain/loss-of-function with orthogonal approaches\",\n      \"pmids\": [\"28476624\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"CLN6 forms an obligate complex with CLN8 (termed EGRESS: ER-to-Golgi relaying of enzymes of the lysosomal system) to recruit lysosomal enzymes at the ER and promote their transfer to the Golgi. The second luminal loop of CLN6 is required for interaction with lysosomal enzymes but is dispensable for interaction with CLN8. CLN6 deficiency causes inefficient ER export of lysosomal enzymes and reduced lysosomal enzyme levels. Mice lacking both CLN6 and CLN8 show no aggravated pathology compared with single knockouts, confirming the two proteins act as a functional unit.\",\n      \"method\": \"Co-immunoprecipitation, protein trafficking assays, CLN6 loop mutagenesis, in vitro and in vivo lysosomal enzyme quantification, double-knockout mouse analysis\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods (Co-IP, mutagenesis, in vivo double KO epistasis, trafficking assays) in single rigorous study\",\n      \"pmids\": [\"32597833\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Graded reduction in CLN6's anti-aggregate activity correlates with disease severity: the late infantile-onset nclf truncation mutant (Arg106ProfsX) abolishes anti-aggregate activity, while adult-onset missense mutants (Arg149Cys, Arg149His) retain partial activity against aggregation-prone αBC mutants.\",\n      \"method\": \"Protein aggregation assays with CLN6 disease mutants overexpressed in HeLa cells, testing activity against multiple αBC aggregation-prone variants\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — single lab with multiple mutants and substrates, mechanistically informative\",\n      \"pmids\": [\"32171521\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"CLN6 deficiency selectively reduces the lysosomal levels of multiple N-glycosylated soluble hydrolases, including several other NCL proteins, as determined by comparative proteomics of isolated lysosomal fractions; confirmed by Western blot and enzymatic activity assays.\",\n      \"method\": \"Proteomic analysis of isolated lysosomal fractions from nclf mouse liver, Western blotting, enzymatic activity assays\",\n      \"journal\": \"Proteomics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — single lab, orthogonal validation (proteomics + Western + enzyme assay) in mouse model\",\n      \"pmids\": [\"34432360\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"CLN6's luminal tail (C-terminal domain) is required for maintaining anti-aggregate activity when co-expressed with truncated CLN6 mutants; the S132CfsX18 truncated mutant nullifies the anti-aggregate activity of co-expressed P299L CLN6 missense mutant through a dominant-negative mechanism involving the luminal tail.\",\n      \"method\": \"Co-expression of CLN6 mutant combinations in cells, protein aggregation assays, deletion and alanine substitution mutagenesis of CLN6 C-terminus\",\n      \"journal\": \"Biomedical research (Tokyo, Japan)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — single lab, systematic mutagenesis with functional readout\",\n      \"pmids\": [\"34380921\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Pro-cathepsin D (proCTSD) prevents aberrant protein aggregation through functional association with CLN6 at the ER membrane; CLN6 depletion abolishes proCTSD's anti-aggregate activity. CTSD was identified as a binding partner of ER-anchored αBC and its pro-peptide integrity is required for anti-aggregate function.\",\n      \"method\": \"Co-immunoprecipitation of ER-anchored αBC binding partners (identifying proCTSD), CLN6 knockdown, CTSD variant overexpression, protein aggregation assays in HeLa cells\",\n      \"journal\": \"Molecular genetics and metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — single lab, multiple orthogonal approaches (Co-IP, knockdown, mutant analysis)\",\n      \"pmids\": [\"39032464\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CLN6 is a non-glycosylated polytopic ER-resident membrane protein (7 transmembrane domains, cytoplasmic N-terminus, luminal C-terminus) that forms an obligate complex with CLN8 (the EGRESS complex) to recruit lysosomal enzymes at the ER and facilitate their transfer to the Golgi, thereby supporting lysosome biogenesis; CLN6 also homodimerizes, interacts with CRMP-2 and pro-cathepsin D, and suppresses aberrant protein aggregation at the ER through the autophagy-lysosome system, while pathogenic mutations lead to rapid proteasome/ERAD-mediated degradation of the mutant protein and downstream lysosomal dysfunction.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"CLN6 is an ER-resident polytopic membrane protein that functions centrally in lysosome biogenesis by forming an obligate complex with CLN8 (the EGRESS complex) to recruit soluble lysosomal enzymes at the ER and facilitate their COPII-mediated transport to the Golgi [PMID:32597833]. CLN6 possesses seven transmembrane domains with a cytoplasmic N-terminus and luminal C-terminus, homodimerizes, and is retained in the ER through determinants in its N-terminal cytosolic domain and transmembrane domains 6–7 [PMID:15010453, PMID:17453415]. Beyond enzyme trafficking, CLN6 cooperates with ER-anchored αB-crystallin and pro-cathepsin D to suppress aberrant protein aggregation through the autophagy–lysosome system, and loss of CLN6 causes accumulation of autophagic substrates and ubiquitinated aggregates in neurons [PMID:28476624, PMID:22536393, PMID:39032464]. Loss-of-function mutations in CLN6 cause variant late-infantile neuronal ceroid lipofuscinosis, with pathogenic mutants undergoing rapid proteasome/ERAD-mediated degradation and graded loss of anti-aggregate activity correlating with disease severity [PMID:11791207, PMID:18811591, PMID:32171521].\",\n  \"teleology\": [\n    {\n      \"year\": 2001,\n      \"claim\": \"Positional cloning identified CLN6 as the gene mutated in variant late-infantile neuronal ceroid lipofuscinosis (vLINCL) in both humans and the nclf mouse, establishing that this novel seven-transmembrane-domain protein is essential for neuronal survival.\",\n      \"evidence\": \"Positional cloning and mutation analysis in patient families and the nclf mouse model\",\n      \"pmids\": [\"11791207\", \"11727201\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Subcellular localization of CLN6 was unknown\",\n        \"Molecular function and pathway involvement were uncharacterized\",\n        \"No protein-level studies had been performed\"\n      ]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"CLN6 was shown to be an ER-resident protein that homodimerizes and whose deficiency impairs lysosomal degradative capacity without affecting cathepsin D processing, establishing that an ER protein can remotely control lysosomal function.\",\n      \"evidence\": \"Immunofluorescence with organelle markers, GFP-tagged CLN6, cross-linking, and lysosomal degradation assays in patient/animal fibroblasts\",\n      \"pmids\": [\"15265688\", \"15010453\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"The mechanism by which an ER protein influences lysosomal enzyme content was unknown\",\n        \"Identity of direct binding partners mediating lysosomal enzyme trafficking was not established\",\n        \"Topology and ER retention determinants were not yet mapped\"\n      ]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Mapping of CLN6 topology (cytoplasmic N-terminus, luminal C-terminus, 7 TMs) and identification of ER-retention determinants in the N-terminal cytosolic domain and TMs 6–7 defined the structural framework for understanding CLN6 function.\",\n      \"evidence\": \"Differential permeabilization, confocal microscopy, and systematic mutagenesis of retention signals in BHK and neuronal cells\",\n      \"pmids\": [\"17453415\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"No direct cargo-binding activity had been demonstrated\",\n        \"Functional significance of homodimerization remained unclear\"\n      ]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Two distinct aspects of CLN6 biology were revealed: interaction with the neurodevelopmental protein CRMP-2, linking CLN6 to neuronal maturation, and demonstration that pathogenic CLN6 mutants are degraded via ERAD involving Derlin-1, p97, and the SEL1L-dependent ubiquitin ligase.\",\n      \"evidence\": \"Co-immunoprecipitation of CLN6–CRMP-2; proteasome inhibitors, Co-IP with ERAD components, and SEL1L siRNA rescue in neuronal-derived cells\",\n      \"pmids\": [\"19235893\", \"18811591\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"CLN6–CRMP-2 interaction lacks reconstitution with purified proteins\",\n        \"Whether ERAD-mediated loss of mutant CLN6 is the primary pathogenic mechanism versus loss of function was unclear\",\n        \"Relationship between CRMP-2 interaction and lysosomal enzyme trafficking was not addressed\"\n      ]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Pulse-chase analysis of multiple pathogenic CLN6 mutations showed mutation-dependent effects on protein synthesis rate and stability, with some mutants degraded by both proteasomal and lysosomal pathways, yet none lost the capacity to dimerize.\",\n      \"evidence\": \"Pulse-chase metabolic labeling, proteasomal and lysosomal inhibitor treatment in patient-derived and transfected cells\",\n      \"pmids\": [\"20020536\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Functional consequence of retained dimerization by mutants was not tested\",\n        \"Whether residual mutant CLN6 retains partial function was unknown\"\n      ]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"CLN6 deficiency was linked to progressive autophagy–lysosome pathway dysfunction, with accumulation of LC3-II, ubiquitinated proteins, and p62 aggregates in nclf neurons, without triggering the unfolded protein response, clarifying that pathology stems from downstream lysosomal failure rather than ER stress.\",\n      \"evidence\": \"Western blot for autophagy markers, ER stress markers, and proteasomal inhibitor treatment in nclf mouse brain\",\n      \"pmids\": [\"22536393\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Causal direction—whether autophagy block is primary or secondary to lysosomal enzyme depletion—was not resolved\",\n        \"No direct mechanistic link between ER-resident CLN6 and autophagosome–lysosome fusion was identified\"\n      ]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Discovery that CLN6 physically associates with ER-anchored αB-crystallin and acts as an effector to suppress protein aggregation via the autophagy–lysosome system established an unexpected proteostasis function for CLN6 at the ER.\",\n      \"evidence\": \"Co-immunoprecipitation, CLN6 siRNA knockdown and overexpression, protein aggregation assays, and lysosomal inhibitor treatment in HeLa cells\",\n      \"pmids\": [\"28476624\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Mechanism by which CLN6 promotes aggregate clearance was not defined\",\n        \"Whether anti-aggregate function is independent of lysosomal enzyme trafficking was not tested\"\n      ]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"The central mechanism of CLN6 was resolved: CLN6 and CLN8 form the EGRESS complex that recruits lysosomal enzymes at the ER for Golgi-directed transport; the second luminal loop of CLN6 mediates enzyme binding while being dispensable for CLN8 interaction, and double-knockout epistasis confirmed the two proteins operate as a single functional unit.\",\n      \"evidence\": \"Co-immunoprecipitation, lysosomal enzyme trafficking assays, CLN6 luminal loop mutagenesis, and CLN6/CLN8 double-knockout mouse phenotyping\",\n      \"pmids\": [\"32597833\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Structural basis of enzyme recognition by the EGRESS complex is unknown\",\n        \"How cargo selectivity for N-glycosylated soluble hydrolases is achieved is not established\",\n        \"Whether EGRESS interacts directly with COPII coat components was not tested\"\n      ]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Genotype–phenotype correlation was mechanistically grounded: graded loss of CLN6 anti-aggregate activity correlated with disease severity, with the nclf truncation abolishing activity and adult-onset missense mutations retaining partial function.\",\n      \"evidence\": \"Protein aggregation assays with multiple CLN6 disease mutants tested against αBC aggregation-prone variants in HeLa cells\",\n      \"pmids\": [\"32171521\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Whether residual anti-aggregate activity predicts disease course in patients was not tested clinically\",\n        \"Relationship between EGRESS function and anti-aggregate activity was not disentangled\"\n      ]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Proteomic analysis confirmed that CLN6 deficiency broadly depletes N-glycosylated soluble hydrolases from lysosomes, including multiple NCL-related enzymes, validating the EGRESS model at the organelle level; separately, the luminal C-terminal tail was shown to be critical for anti-aggregate activity and a truncated CLN6 mutant exerts dominant-negative effects.\",\n      \"evidence\": \"Proteomic analysis of isolated lysosomal fractions from nclf liver, Western blot, enzyme assays; co-expression mutagenesis and aggregation assays\",\n      \"pmids\": [\"34432360\", \"34380921\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Mechanism of dominant-negative effect through the luminal tail is not resolved at a structural level\",\n        \"Whether tissue-specific differences in lysosomal enzyme depletion exist was not explored\"\n      ]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Pro-cathepsin D was identified as a functional partner of CLN6 in the anti-aggregate pathway, requiring CLN6 for its ER-localized anti-aggregate activity and linking a known NCL enzyme to CLN6-dependent proteostasis at the ER.\",\n      \"evidence\": \"Co-immunoprecipitation of ER-anchored αBC partners identifying proCTSD, CLN6 knockdown, CTSD variant overexpression, aggregation assays in HeLa cells\",\n      \"pmids\": [\"39032464\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Whether proCTSD is an EGRESS cargo that also has a pre-export ER function, or whether these are separable roles, is unresolved\",\n        \"Direct physical interaction between CLN6 and proCTSD has not been demonstrated with purified components\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key open questions include the structural basis of CLN6–CLN8 EGRESS complex assembly and cargo recognition, whether CLN6's anti-aggregate function is mechanistically distinct from its enzyme-trafficking role, how EGRESS interfaces with COPII-mediated ER export, and whether therapeutic stabilization of mutant CLN6 can restore lysosomal biogenesis in vivo.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"No high-resolution structure of CLN6 or the EGRESS complex exists\",\n        \"Mechanistic relationship between EGRESS trafficking function and anti-aggregate function is unresolved\",\n        \"COPII interaction and ER-exit mechanism for the EGRESS–cargo complex are uncharacterized\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [11, 13]},\n      {\"term_id\": \"GO:0038024\", \"supporting_discovery_ids\": [11]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [1, 4, 11]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-9612973\", \"supporting_discovery_ids\": [9, 10]},\n      {\"term_id\": \"R-HSA-9609507\", \"supporting_discovery_ids\": [11, 13]},\n      {\"term_id\": \"R-HSA-1852241\", \"supporting_discovery_ids\": [3, 11, 13]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [7, 8]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [0, 12]}\n    ],\n    \"complexes\": [\n      \"EGRESS complex (CLN6–CLN8)\"\n    ],\n    \"partners\": [\n      \"CLN8\",\n      \"CRMP2\",\n      \"CRYAB\",\n      \"CTSD\",\n      \"DERL1\",\n      \"VCP\",\n      \"SEL1L\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}